Biotech · Private company
Origin Biosciences
Track this companyFree. Adds Origin Biosciences to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- ORGN001 (formerly ALXN1101)Phase 3 · Molybdenum Cofactor Deficiency, Type AClinicalTrials.gov · fetched Nov 12, 2026
- ALXN1101Phase 1 · Molybdenum Cofactor Deficiency (MoCD)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type APHASE2_PHASE3 · COMPLETED · started May 1, 2016ClinicalTrials.gov NCT02629393 · fetched Nov 12, 2026
- Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMPPHASE2 · COMPLETED · started Apr 1, 2014ClinicalTrials.gov NCT02047461 · fetched Nov 12, 2026
- A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase DeficienciesCOMPLETED · started Aug 1, 2013ClinicalTrials.gov NCT01735188 · fetched Nov 12, 2026
- Phase 1 Single Dose Study of ALXN1101 in Healthy VolunteersPHASE1 · COMPLETED · started Jun 1, 2013ClinicalTrials.gov NCT01894165 · fetched Nov 12, 2026
- A Retrospective, Observational, Noninterventional Data Collection Study for Patients With Molybdenum Cofactor Deficiency Who Have Been Previously Treated With Cyclic Pyranopterin Monophosphate (cPMP)COMPLETED · started Nov 1, 2012ClinicalTrials.gov NCT01640717 · fetched Nov 12, 2026